Those in the sequential group (FAP + CLDN18.2) received the prior FAP-mBBZ CAR-T cells on day 10, and CLDN18.2-mBBZ CAR-T cells were subsequently infused on day 18 after tumor cell inoculation (Fig. 4a). Here, FAP is linked to neoplasm.